Vyepti 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
X/0011 
Annex I_2.(c) Change or addition of a new 
12/10/2023 
07/12/2023 
SmPC, 
strength/potency 
Labelling and 
PL 
PSUSA/10966
Periodic Safety Update EU Single assessment - 
28/09/2023 
n/a 
PRAC Recommendation - maintenance 
/202302 
eptinezumab 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
II/0012 
B.II.f.1.c - Stability of FP - Change in storage 
21/09/2023 
07/12/2023 
SmPC and PL 
conditions for biological medicinal products, when the 
stability studies have not been performed in 
accordance with an approved stability protocol 
IB/0015/G 
This was an application for a group of variations. 
19/09/2023 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IA/0014/G 
This was an application for a group of variations. 
13/07/2023 
n/a 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
II/0008 
B.II.b.3.c - Change in the manufacturing process of 
20/04/2023 
n/a 
the finished or intermediate product - The product is 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a biological/immunological medicinal product and the 
change requires an assessment of comparability 
II/0005/G 
This was an application for a group of variations. 
20/04/2023 
n/a 
B.I.b.2.z - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.b.z - Change in control of the AS - Other 
variation 
B.I.b.z - Change in control of the AS - Other 
variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
Page 3/5 
 
 
 
 
 
 
 
 
 
PSUSA/10966
Periodic Safety Update EU Single assessment - 
16/03/2023 
n/a 
PRAC Recommendation - maintenance 
/202208 
eptinezumab 
IB/0009 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
15/02/2023 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0007/G 
This was an application for a group of variations. 
04/01/2023 
n/a 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0004 
B.II.e.5.a.2 - Change in pack size of the finished 
28/11/2022 
29/06/2023 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
PSUSA/10966
Periodic Safety Update EU Single assessment - 
29/09/2022 
n/a 
PRAC Recommendation - maintenance 
/202202 
eptinezumab 
IAIN/0003 
B.II.b.1.a - Replacement or addition of a 
16/08/2022 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
II/0001 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
16/06/2022 
29/06/2023 
SmPC and PL 
new quality, preclinical, clinical or pharmacovigilance 
data 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
